Tanezumab effectively and safely reduces OA hip pain and improves physical function
Tanezumab Reduces Osteoarthritic Hip Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III TrialArthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
627 patients with hip osteoarthritis (OA) were randomized to receive either 2.5 mg, 5 mg, or 10 mg doses of intravenous tanezumab (monoclonal antibody against nerve growth factor) or a placebo. The purpose was to compare each treatment's efficacy in lowering pain. After 32 weeks, results indicated that patients who were treated with tanezumab had significantly greater improvements in pain and phys...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue